Conference Day One
Wednesday 30th August 2023
7:45 am
Registration & Welcome Coffee
8:45 am
Chair’s Opening Remarks
Enhancing the Stability of Viral Vectors via Next Gen Cell Line Engineering & Formulation
9:00 am Development of Capsid Engineering
Synopsis
- Advancing capsid engineering to reduce immunogenicity
- Maximisation of stability via engineering
- Discussing the specifics of enhancing capsid design for AAV vectors
9:30 am Characterisation of AAVs & Other Gene Therapy Vectors Using TEM to Assess Critical Quality Attributes
Synopsis
- Gain business-critical insights into CQAs such as morphology, purity, integrity, aggregation, size and circularity distribution, and transgene incorporation and characterisation
- Wholistic GMP-certified TEM services for imaging and analysis of gene therapy vectors using cryoTEM and nsTEM
- Supporting the development of novel therapies with reliable and traceable data from ultra-low sample volumes
10:00 am
Speed Networking & Morning Coffee
11:00 am Solving The Deep-Frozen Challenge: Development of a Formulation to Stabilise Oncolytic Viruses
Synopsis
- Development of a formulation to stabilise lypholised oncolytic viruses
- Challenges and optimisation of the lypholisation process
- Stability data of lypholised oncolytic virus at 2-8°C
11:30 am Ensuring Compliance through Particle Analytics & Formulation
Synopsis
- Regulatory requirements for ATMPs
- Increasing process robustness by control of particle formation
- Particle analytics from bench to clinic
12:00 pm
Networking Lunch Break
Increasing Upstream Process Development Efficiency
1:00 pm The Applicability of Different Viral Vector Production Techniques
Synopsis
- Comparison of the different viral vector production techniques to decide the most appropriate
- Introduction to baculovirus system to improve scalability and cost efficiency of AAV production
- Presenting some of VectorY’s results of increased production using the baculovirus method
1:30 pm Increasing AAV Titre via Transfection Improvement to Reduce Costs
Synopsis
- Selecting the correct critical raw materials
- Defining the key parameters for transient transfection productions at small scale to ensure a scalable process
- Data presentation on the scale-up of production using a stirred tank bioreactor
2:00 pm Novel Vector Design for Enhanced Expression & Genetic Payload Capacity
Synopsis
- Adopting advanced sequencing techniques to design your novel plasmid to maximise expression
- Evaluate how this can impact on your viral vector performance and quality
- Streamlining your upstream process via tightened control of plasmid and vector to regain speed
2:30 pm Developing a Future Proof Commercially Viable Lentiviral Vector Manufacturing Process
Synopsis
- Development of a transient suspension process for commercialism
- Downstream process strategy for large scale LVV production
- Characterisation of the process platform
3:00 pm
Afternoon Refreshments & Poster Session
Yield Matters: Creating Robustness through Downstream Processing of Your Viral Vectors
3:45 pm Downstream Process Development & Manufacturing of Recombinant AAV
Synopsis
- Advancements in the downstream process development of UCB’s AAV candidate
- Developments in the manufacturability of this vector to promote scalability
- The challenges of creating a scalable rAAV product
4:15 pm Roundtable Discussion: Improvement of Downstream Efficiency to Maximize Yield
Synopsis
- Optimising purification recovery to maximise yield
- Implementation of equipment to automate the purification process to increase reproducibility and yield
- Large scale chromatography to overcome diffusion-limited beads for efficient purification